Skip to main content
Explore URMC
URMC / Alzheimers Care

AD-CARE: Alzheimer's Disease Care, Research and Education Program


Lecanemab (Leqembi) was recently given accelerated FDA approval for the treatment of mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia. This medication is an infusion that will be administered twice monthly in an infusion center and requires regular monitoring for side effects through a series of head MRIs. If you are a patient at the URMC Memory Care Program, please contact your provider if you are interested in finding out if you or your family member qualify for treatment with lecanemab. If you are interested in finding out more about clinical trial opportunities at AD-CARE, contact us at 585-602-5200.


Advancement of clinical research is a fundamental mission of the AD-CARE program.  We participate in a number of national and international studies that focus on different aspects of Alzheimer's Disease.

Specialists who have expertise in dementia treatment and research direct the day-to-day activities of our clinical studies.

We conduct studies concerning:

  • Prevention of Alzheimer's Disease
  • Early memory problems or cognitive impairment
  • Diagnostic tools used for Alzheimer's Disease
  • Behavioral disturbances in persons with Alzheimer's Disease



Forget-Me-Not Fund

Help support Alzheimer's Disease clinical research in the Rochester area by making a donation to the Forget-Me-Not Fund.